Mayo Clinic Laboratories, a global leader in advanced laboratory testing, and Lucence, a pioneer in molecular diagnostics, have formed a strategic collaboration to expand international access to cutting-edge cancer detection services. This partnership combines the strengths of both organizations to deliver improved outcomes for patients worldwide. The collaboration will focus on making Lucence’s innovative LiquidHALLMARK® technology available through Mayo Clinic Laboratories’ global network.
Technology Integration
Lucence, operating CLIA-certified and CAP-accredited laboratories in California and Singapore, will provide its LiquidHALLMARK® platform through Mayo Clinic Laboratories. This ultra-sensitive next-generation sequencing liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) to identify clinically relevant biomarkers across various cancer types. The Medicare-covered test delivers actionable findings by matching genomic results with targeted therapies, including detailed descriptions of each discovery and relevant clinical trials.
Leadership Perspectives
Dr. William Morice, President and CEO of Mayo Clinic Laboratories, emphasized the significance of this collaboration: “We look forward to offering LiquidHALLMARK to provide physicians and their patients with critical insights for treatment decisions. Incorporating this test into our catalog supports our goal of delivering comprehensive testing options for serious or complex cases.” Dr. Min-Han Tan, Founder and CEO of Lucence, added: “Partnering with Mayo Clinic Laboratories advances our shared mission of making innovative cancer testing accessible globally, helping healthcare providers deliver personalized cancer care.”
Test Capabilities and Reporting
The LiquidHALLMARK® test stands out for its comprehensive reporting features, which include graphical representations of cancer genomic profiles and tumor evolution over time. Each report provides detailed information about genomic findings, highlighting their relevance to the patient’s specific cancer type and existing functional evidence. This level of detail supports clinicians in developing personalized treatment plans and tracking disease progression.
Organizational Impact
As a for-profit, wholly owned subsidiary of Mayo Clinic, Mayo Clinic Laboratories will use any revenue generated from this partnership to support Mayo Clinic’s nonprofit mission in patient care, education, and research. This collaboration represents a significant advancement in oncologic diagnostics, combining Lucence’s liquid biopsy expertise with Mayo Clinic Laboratories’ global reach and clinical laboratory leadership to equip healthcare providers with tools for informed decision-making and personalized cancer care.
Related topics:
